Genmab A/S (NASDAQ:GMAB – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $50.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 70.01% from the company’s previous close.
Several other analysts have also commented on the company. Citigroup lowered Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. Truist Financial reissued a “buy” rating and set a $50.00 price target (down previously from $54.00) on shares of Genmab A/S in a report on Tuesday, February 20th. DNB Markets raised Genmab A/S from a “sell” rating to a “buy” rating in a report on Wednesday, November 8th. UBS Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, December 6th. Finally, Deutsche Bank Aktiengesellschaft raised Genmab A/S from a “hold” rating to a “buy” rating in a research note on Friday, November 10th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $48.50.
View Our Latest Research Report on Genmab A/S
Genmab A/S Price Performance
Institutional Investors Weigh In On Genmab A/S
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. raised its position in Genmab A/S by 21.0% during the second quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company’s stock valued at $311,210,000 after purchasing an additional 1,420,915 shares during the period. BlackRock Inc. grew its stake in shares of Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock valued at $198,799,000 after buying an additional 86,571 shares during the last quarter. Capital International Investors grew its stake in shares of Genmab A/S by 2.2% during the second quarter. Capital International Investors now owns 4,197,060 shares of the company’s stock valued at $157,180,000 after buying an additional 88,355 shares during the last quarter. Macquarie Group Ltd. grew its stake in shares of Genmab A/S by 11.1% during the first quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company’s stock valued at $131,580,000 after buying an additional 347,437 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Genmab A/S by 5.8% during the first quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock valued at $120,618,000 after buying an additional 183,578 shares during the last quarter. 6.29% of the stock is currently owned by hedge funds and other institutional investors.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
- Five stocks we like better than Genmab A/S
- Best Stocks Under $5.00
- Can You Invest in ChatGPT Stock? Find Out Here
- Comparing and Trading High PE Ratio Stocks
- Vital Farm’s Earnings: More than Sunny Side Up
- What is the FTSE 100 index?
- How to Invest in Artificial Intelligence in These Simple Ways
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.